Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04471415
Title First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Dracen Pharmaceuticals, Inc.
Indications

lung non-small cell carcinoma

hypopharynx cancer

head and neck squamous cell carcinoma

oral cavity cancer

Advanced Solid Tumor

laryngeal squamous cell carcinoma

oropharynx cancer

Therapies

DRP-104

Atezolizumab + DRP-104

Age Groups: adult | senior
Covered Countries USA | DEU


No variant requirements are available.